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the question arises of whether this new combination therapy will 
also be suitable for PEG-IFN- and ribavirin-resistant patients with 
chronic kidney disease.
Tilman B. Drüeke
Daily dialysis reduces pulse  
wave velocity in chronic 
hemodialysis patients
Di Micco et al., Hypertens Res advance online publication, 16 January 2012, 
doi:10.1038/hr.2011.230
Cardiovascular disease remains the major cause of death of dialysis 
patients. In the general population, aortic stiffness is a predictor of 
cardiovascular morbidity and mortality. Whereas aortic stiffness 
once could be determined only by invasive monitoring, it now can 
be readily determined noninvasively by pulse wave velocity (PWV) 
techniques. As more centers use these techniques, preliminary 
reports show an association between PWV and both cardiovascu-
lar morbidity and mortality in dialysis patients. In dialysis patients, 
there has been debate as to the causes of increased PWV, ranging 
from simple volume overload to increased cationic content of the 
media and vascular interstitial tissues, as studies in the 1930s and 
1950s reported increased sodium and calcium content in arteries 
taken from patients with hypertension.
Di Micco and colleagues randomized 60 patients matched for 
PWV who were receiving standard thrice-weekly dialysis to 1 week 
of either standard thrice-weekly hemodialysis (12 hours) or more 
frequent dialysis (six sessions of 2.5–3.0 hours), and then crossed 
the groups over. Three groups of patients were identified: those 
with normal predialysis and postdialysis PWV, those with high 
predialysis but normal postdialysis PWV, and those with high 
predialysis and postdialysis PWV. More frequent dialysis caused 
90% of the patients in the group with high predialysis and nor-
mal postdialysis PWV to move to the group with normal pre- and 
postdialysis PWV.
These changes occurred with no significant difference in small-
solute clearance, and with the same dialysate electrolyte composi-
tion. However, during the week of more frequent dialysis, there was 
a substantial weight loss of around 4 kg, suggesting that volume 
plays a key role in determining changes in PWV in dialysis patients 
in the short term.
Andrew Davenport
Mutations in kelch-like 3 and  
cullin 3 cause hypertension  
and electrolyte abnormalities
Boyden et al., Nature 2012; 482: 98–102; doi:10.1038/nature10814
Pseudohypoaldosteronism type II (PHAII, or Gordon’s 
syndrome) is a rare Mendelian syndrome characterized by 
Revolution in the treatment  
of hepatitis C virus infection?
Lok et al., N Engl J Med 2012; 366: 216–224; doi:10.1056/NEJMoa1104430
Hepatitis C virus (HCV) (Figure) infection is a very common cause 
of chronic liver disease, which frequently causes cirrhosis and 
hepatocellular carcinoma. There are six major HCV genotypes, 
and genotype 1 is the most difficult to treat. Treatment of chronic 
hepatitis C is based on the combination of pegylated interferon-a 
(PEG-IFN-a) and ribavirin. Unfortunately, only 40–50% of HCV 
genotype 1-infected patients have a sustained virologic response 
to this combination therapy. Retreatment with triple therapy—a 
protease inhibitor, peginterferon, and ribavirin—yields sustained 
response rates of only an additional 15–30%. Lok et al. explored the 
hypothesis that HCV genotype 1 carriers who failed to respond to 
PEG-IFN plus ribavirin might benefit from treatment with multiple 
direct-acting antiviral agents. In an open-label, phase 2a study, they 
randomly administered the NS5A replication complex inhibitor 
daclatasvir and the NS3 protease inhibitor asunaprevir, either alone 
(group A, 11 patients) or in combination with PEG-IFN and riba-
virin (group B, 10 patients) for 24 weeks. The primary end point 
was the percentage of patients with a sustained virologic response 
12 weeks after the end of the treatment period. All 10 patients in 
group B had a sustained viral response at 12 weeks after treatment, 
and nine patients at 24 weeks after treatment. In group A, four 
patients had a sustained virologic response at 12 and 24 weeks after 
treatment, but six patients had viral breakthrough while receiving 
therapy, and one patient relapsed after the treatment period. Clini-
cally, diarrhea was the most common adverse event.
The results of this preliminary study are extremely encouraging. 
We probably are on the threshold of a treatment revolution for 
patients with HCV infection. Furthermore, since the prevalence 
of HCV carriers is elevated in dialysis patients and in kidney trans-
plant recipients, who are at particularly high risk of liver injury, 
HCV viral cycle. The HCV life cycle starts with virion attachment to its 
specific receptor (not clearly identified). The HCV RNA genome serves as 
a template for viral replication and as a viral mRNA for viral production. 
It is translated into a polyprotein that is cleaved by proteases. Then, viral 
assembly occurs. Potentially, each step of the viral cycle is a target for 
drug development.
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hypertension, hyperkalemia, metabolic acidosis, and low 
plasma renin activity and aldosterone concentrations. Dis-
ease features of PHAII are reversed by thiazide diuretics, 
which inhibit the Na–Cl cotransporter (NCC) in the dis-
tal nephron. In a small fraction of PHAII kindreds, gain-
of-function mutations in WNK affect NCC, leading to 
increased salt reabsorption with subsequent hypertension 
and inhibition of K+ secretion due to reduction of lumen 
electronegativity. Boyden and colleagues studied a cohort 
of 52 PHAII kindreds, including 126 affected subjects, and 
found mutations in WNK1 or WNK4 in only seven kin-
dreds (13%). Thus, they used exome sequencing of subjects 
without WNK mutations. Exome sequencing is a strategy to 
selectively sequence the coding regions of the genome as an 
alternative to whole-genome sequencing; it has become fea-
sible by massively parallel DNA sequencing, the so-called 
next-generation sequencing. Exons constitute about 1% of 
the human genome, and exome sequencing is much cheaper 
and faster than whole-genome sequencing.
The authors identified mutations in kelch-like 3 (KLHL3) or 
cullin 3 (CUL3) in 24 and 17 PHAII kindreds (46% and 33%), 
respectively. KLHL3 and CUL3 are expressed in the distal 
nephron as well as NCC and are components of cullin–RING E3 
ligase (CRL) complexes that ubiquitinate substrates. It is likely 
that mutations in KLHL3 or CUL3 may abrogate ubiquitina-
tion of their substrates. It remains unknown whether a KLHL3–
CUL3 CRL acts directly on NCC, or whether KLHL3–CUL3 and 
WNKs operate within the same pathway.
The utility of exome sequencing was also shown in the recent 
identification of frequent mutations in clear-cell renal-cell car-
cinoma, and the responsible genes encoded ubiquitin-medi-
ated proteolysis pathway components involved in regulation 
of HIF1a and HIF2a in the tumors.1 Using this technique, the 
study by Boyden et al. clearly establishes a fundamental role for 
components involved in ubiquitination, KLHL3 and CUL3, in 
blood pressure, K+, and pH homeostasis.
Masaomi Nangaku
1Guo et al., Nat Genet 2011; 44: 17–19.
A genomic storm in critically 
injured humans
Xiao et al., J Exp Med 2011; 208: 2581–2590; doi:10.1084/jem.20111354
How the human immune system successfully responds to 
injury is a major factor in survival of our species. In this 
remarkable and important collaborative multicenter study, 
Xiao et al. used a genome-wide expression profile approach 
to investigate the immune response to trauma in two groups 
of patients who experienced blunt trauma or burn injury. 
The genome-wide responses induced in peripheral blood 
leukocytes by severe blunt trauma and by low-dose bacterial 
endotoxin infusion, detected by Affymetrix U133 GeneChip, 
were virtually identical, with induction of innate immunity 
genes and simultaneous suppression of adaptive immuno-
logic genes. The study then investigated the transcriptomic 
response in two groups of critically ill patients, those with 
‘uncomplicated’ recovery from trauma (<5 days) and those 
with ‘complicated’ recovery (>14 days to recover, no recovery 
by 28 days, or death), to question whether the array profiles 
differed between these two clinical end points. Surpris-
ingly, the only difference between the groups in the genomic 
response was qualitative, with identical sets of genes being 
switched on and suppressed irrespective of clinical end point; 
the difference was in the time to maximal gene expression and 
the duration of the response and its return to baseline (Figure, 
right). Importantly, no set of genes could be identified as pre-
dicting better recovery. The data suggest that humans have a 
common inflammatory transcriptome pattern in response to 
critical illness, which occurs rapidly following injury (4–12 
hours) and has a sustained expression pattern up to weeks 
after the insult. Thus, this paper challenges the current para-
digm of inflammatory response to injury. Under the older 
model, largely based on small-animal models, the systemic 
inflammatory immune response (SIRS) to trauma activates 
the innate immune response, which is followed by a sup-
pressive compensatory anti-inflammatory response (CARS) 
that affects the adaptive immune response (Figure, left). The 
new data provided by this study, acquired from direct human 
observation, indicate that both responses are synchronous and 
not disparate in timing (Figure, right).
These novel findings also have important implications for 
organ donation and transplantation, as they clearly demonstrate 
an early and sustained innate immune activation in critically 
ill humans, which may potentially affect transplanted organs.
P. Toby Coates
A genomic storm: refining the immune, inflammatory paradigm in 
trauma. Left: The current paradigm explains complications of severe 
injury as a result of excessive proinflammatory responses (SIRS) followed 
temporally by CARS and suppression of adaptive immunity. A second-hit 
phenomenon results from sequential insults, which leads to more severe, 
recurrent SIRS and organ dysfunction. Right: The proposed new paradigm 
involves simultaneous and rapid induction of innate immunity genes 
(both pro- and anti-inflammatory) and suppression of adaptive immunity 
genes. Complicated recoveries are delayed, resulting in a prolonged, 
dysregulated immune–inflammatory state. CARS, compensatory 
anti-inflammatory response syndrome; SIRS, systemic inflammatory 
response syndrome. 
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